Form 4: REGENXBIO Director George Migausky Receives Equity Compensation Awards

REGENXBIO Inc. Director George V. Migausky was granted 7,768 restricted stock units and 39,815 stock options as part of his compensation, aligning his interests with shareholders.

Summary

• REGENXBIO Inc. Director George V. Migausky reported the acquisition of 7,768 shares of common stock underlying a time-based restricted stock unit (RSU) award.
• These RSU shares were acquired at a price of $0.00 and will vest 100% on May 1, 2026, subject to continuous service.
• Migausky also acquired 39,815 stock options (right to buy) at an exercise price of $8.85 per share, with an acquisition price of $0.00.
• The stock options will vest in 12 equal monthly installments following May 30, 2025, also subject to continuous service.
• Following these transactions, George V. Migausky beneficially owns 19,054 shares of common stock and 39,815 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The sentiment is positive as it reflects standard equity compensation for a director, which aligns their interests with the company's long-term performance and shareholder value. It's a routine, expected event rather than a significant market-moving announcement.

Positives

• The granting of restricted stock units and stock options to a director aligns management's interests with those of shareholders, encouraging long-term value creation.
• The awards are part of standard compensation practices, indicating ongoing commitment from the director to the company.

Future Outlook

The document details future vesting schedules for the awarded equity, indicating that the RSU shares will vest on May 1, 2026, and stock options will vest monthly over 12 installments starting May 30, 2025, contingent on continuous service.

Industry Context

This Form 4 filing is a routine disclosure of insider equity compensation, common across all industries, particularly in publicly traded companies where aligning executive and director incentives with shareholder value is a key governance practice.

Stakeholder Impact

• Shareholders: The equity awards align the director's financial interests with the company's stock performance, potentially benefiting shareholders through improved governance and strategic decisions aimed at increasing share value.

Next Steps

• Vesting of 7,768 RSU shares on May 1, 2026.
• Monthly vesting of 39,815 stock options over 12 installments starting May 30, 2025.

Key Dates

Keywords

REGENXBIO, RGNX, Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Options, Equity Compensation, Beneficial Ownership, Director Compensation